Literature DB >> 26454093

Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure.

Selene Araya1, Ester Lovsin-Barle1, Susanne Glowienke2.   

Abstract

Pharmaceutical intermediates (IM) are used in the synthesis of active pharmaceutical ingredients. They are not intended for human administration, yet employees may be exposed to IM during the manufacturing process. In the context of occupational health, hazard assessment of IM is needed to identify potential intrinsic hazards which could cause unwanted adverse effects. In particular, a carcinogenic potential influences the protection strategy in the workplace. DNA reactive substances may, even if present at very low levels, lead to mutations and therefore, potentially cause cancer. The use of in silico methods to predict mutagenicity is increasingly acknowledged and implemented in the recently released ICH M7 guideline for the limitation of DNA reactive impurities. In this study we investigate the possibility to apply (quantitative) structure-activity-relationships ((Q)SARs) during hazard identification to reduce the number of Ames tests needed for a hazard assessment of IM while maintaining high standards of protection of employees. Ames test outcomes for 188 substances used in the pharmaceutical production were compared with their in silico predictions using two different (Q)SAR methodologies (knowledge based and statistical) complemented by expert knowledge. The results of the analysis showed that a negative prediction for mutagenicity provides a high confidence that the IM is not mutagenic in the Ames test with the negative predictive value of 97%. On the other hand the positive predictive value was only 57% and therefore considered too low to reliably consider positive predicted IM to be mutagenic. In order to avoid any unnecessary burden for occupational health purposes caused by falsely positive predicted IM, all positive predicted IM and those with insufficient coverage by the in silico systems are submitted to an Ames test to verify or reject the prediction. It is shown that the described in silico prediction approach ensures appropriate protection strategy of the employees. Resources for performing Ames tests which do not add additional or new information for the purpose of hazard assessment could be reduced.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  (Q)SAR; Ames test; Hazard assessment; In silico; Mutagenicity; Occupational exposure; Pharmaceutical intermediates; Structural alert

Mesh:

Substances:

Year:  2015        PMID: 26454093     DOI: 10.1016/j.yrtph.2015.10.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  1 in total

1.  Transitioning to composite bacterial mutagenicity models in ICH M7 (Q)SAR analyses.

Authors:  Curran Landry; Marlene T Kim; Naomi L Kruhlak; Kevin P Cross; Roustem Saiakhov; Suman Chakravarti; Lidiya Stavitskaya
Journal:  Regul Toxicol Pharmacol       Date:  2019-10-03       Impact factor: 3.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.